Clinical Trial Update: ThermaChoice III Under Local Sedation in the Office Setting [NA]

View source ↗

Summary

The ThermaChoice III endometrial ablation trial, conducted under local sedation in an office setting for heavy menstrual bleeding, has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Menorrhagia

Drugs mentioned

• ThermaChoice III (thermal endometrial ablation device)

Snippet

Sponsor: Female Pelvic Medicine & Urogynecology Institute of Michigan | Conditions: Heavy Uterine Bleeding | NA | Status: COMPLETED